XML 41 R19.htm IDEA: XBRL DOCUMENT
v3.23.1

Share Options | 12 Months Ended
--- | ---
Dec. 31, 2022
Share Options [Abstract] |
SHARE OPTIONS | NOTE 12 - SHARE OPTIONS Share option plan: On January 11, 2015, the Company’s Board of Directors approved and adopted the 2015 Share Incentive Plan (the “Plan”), pursuant to which the Company’s Board of Directors may award share options to purchase the Company’s Ordinary Shares as well as restricted shares, RSUs and other share-based awards to designated participants. Subject to the terms and conditions of the Plan, the Company’s Board of Directors has full authority in its discretion, from time to time and at any time, to determine (i) the designate participants; (ii) the terms and provisions of the respective award agreements, including, but not limited to, the number of share options to be granted to each optionee, the number of shares to be covered by each share option, provisions concerning the time and the extent to which the share options may be exercised and the nature and duration of restrictions as to the transferability or restrictions constituting substantial risk of forfeiture and to cancel or suspend awards, as necessary; (iii) determine the fair market value of the shares covered by each award; (iv) make an election as to the type of approved 102 Option under Israeli tax law; (v) designate the type of share options; (vi) take any measures, and to take actions, as deemed necessary or advisable for the administration and implementation of the Plan; (vii) interpret the provisions of the Plan and to amend from time to time the terms of the Plan. The Plan permits the grant of up to 2,069,280 share Ordinary Shares subject to adjustments set in the Plan. As of December 31, 2022, considering the effect of previously exercised share options, there were 355,530 Ordinary Shares available for future issuance under the Plan. The following table presents the Company’s share option activity for employees and members of the Board of Directors of the Company under the Plan for the years ended December 31, 2022, 2021 and 2020:
|  | Number of Share Options |  |  | Weighted Average Exercise Price $ |  |  | Weighted average remaining contractual life (years) |  |  | Intrinsic value $ |
Outstanding as of December 31, 2019 |  |  | 1,291,810 |  |  |  | 1.65 |  |  |  | 5.94 |  |  |  | 194 |
Granted |  |  | 353,960 |  |  |  | 1.80 |  |  |  | 9.35 |  |  |  |  |
Exercised |  |  | (9,800 | ) |  |  | 1.15 |  |  |  | - |  |  |  |  |
Forfeited or expired |  |  | (381,970 | ) |  |  | 1.75 |  |  |  | - |  |  |  |  |
Outstanding as of December 31, 2020 |  |  | 1,254,000 |  |  |  | 1.70 |  |  |  | 6.12 |  |  |  | 125 |
Exercisable as of December 31, 2020 |  |  | 839,665 |  |  |  | 1.50 |  |  |  | 4.73 |  |  |  | 252 |
|  | Number of Share Options |  |  | Weighted Average Exercise Price $ |  |  | Weighted average remaining contractual life (years) |  |  | Intrinsic value $ |
Outstanding as of December 31, 2020 |  |  | 1,254,000 |  |  |  | 1.70 |  |  |  | 6.12 |  |  |  | 125 |
Granted |  |  | 214,688 |  |  |  | 2.05 |  |  |  | 9.64 |  |  |  |  |
Forfeited or expired |  |  | (101,520 | ) |  |  | 1.80 |  |  |  | - |  |  |  |  |
Outstanding as of December 31, 2021 |  |  | 1,367,168 |  |  |  | 1.75 |  |  |  | 5.72 |  |  |  | 4,860 |
Exercisable as of December 31, 2021 |  |  | 927,988 |  |  |  | 1.60 |  |  |  | 4.25 |  |  |  | 3,429 |
|  | Number of Share Options |  |  | Weighted Average Exercise Price $ |  |  | Weighted average remaining contractual life (years) |  |  | Intrinsic value $ |
Outstanding as of December 31, 2021 |  |  | 1,367,168 |  |  |  | 1.75 |  |  |  | 5.72 |  |  |  | 4,860 |
Granted |  |  | 286,875 |  |  |  | 1.83 |  |  |  |  |  |  |  |  |
Forfeited or expired |  |  | (83,052 | ) |  |  | 1.45 |  |  |  | - |  |  |  |  |
Outstanding as of December 31, 2022 |  |  | 1,570,991 |  |  |  | 1.78 |  |  |  | 4.97 |  |  |  | 2,435 |
Exercisable as of December 31, 2022 |  |  | 1,048,297 |  |  |  | 1.70 |  |  |  | 3.2 |  |  |  | 1,677 |
The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the deemed fair value of the Company’s Ordinary Shares on the last day of each of the applicable reported period and the exercise price, multiplied by the number of in-the-money share options) that would have been received by the share option holders had all share options holders exercised their share options on December 31 of each of the reported period. This amount is impacted by the changes in the fair market value of the Company’s Ordinary Share. The outstanding and exercisable share options as of December 31, 2022 have been separated into ranges of exercise prices, as follows:
Exercise price |  | Share options outstanding as of December 31, 2022 |  |  | Weighted average remaining contractual term (years) |  |  | Share options exercisable as of December 31, 2022 |  |  | Weighted average remaining contractual term (years) |
$ |  |  |  |  | $ |  |  |  |  |  | $ |
0.00 |  |  | 152,640 |  |  |  | 2.42 |  |  |  | 152,640 |  |  |  | 1.03 |
1.14 |  |  | 228,480 |  |  |  | 1.39 |  |  |  | 228,480 |  |  |  | 1.39 |
1.67 |  |  | 43,200 |  |  |  | 2.21 |  |  |  | 43,200 |  |  |  | 2.21 |
1.83 |  |  | 982,870 |  |  |  | 6.75 |  |  |  | 489,239 |  |  |  | 4.70 |
3.2 |  |  | 35,001 |  |  |  | 6.45 |  |  |  | 10,938 |  |  |  | 6.45 |
3.79 |  |  | 60,000 |  |  |  | 1.59 |  |  |  | 60,000 |  |  |  | 1.59 |
4.17 |  |  | 28,800 |  |  |  | 3.03 |  |  |  | 28,800 |  |  |  | 3.03 |
5.12 |  |  | 40,000 |  |  |  | 6.54 |  |  |  | 35,000 |  |  |  | 6.54 |
|  |  | 1,570,991 |  |  |  |  |  |  |  | 1,048,297 |  |  |  |  |
The weighted average grant date fair value of share options granted during the years ended December 31, 2022, 2021 and 2020 was $0.51, $0.44 and $0.20 per share option, respectively. During the years ended December 31, 2022 and 2021, share options have not been exercised into Ordinary Shares. During the year ended December 31, 2020, certain employees exercised 9,800 share options into the same number of Ordinary Shares for total consideration of $11. The following table presents the assumptions used to estimate the fair values of the share options granted in the reported periods presented:
|  | Year ended December 31 |
|  | 2022 |  |  | 2021 |  |  | 2020 |
Volatility (%) |  |  | 61.49 | % |  |  | 64.75 | % |  |  | 61.89%-61.91 | %
Risk-free interest rate (%) |  |  | 3.64%-3.85 | % |  |  | 0.09 | % |  |  | 0.03%-0.04 | %
Dividend yield (%) |  |  | - |  |  |  | - |  |  |  | - |
Expected life (years) |  |  | 6.25 |  |  |  | 6.25 |  |  |  | 6.25 |
Exercise price ($) |  |  | 1.83 |  |  |  | 1.80-3.20 |  |  |  | 1.80 |
Share price ($) |  |  | 3.30 |  |  |  | 3.20 |  |  |  | 1.80 |
As of December 31, 2022, there was $1,029 of unrecognized compensation expense related to unvested share options. The Company recognizes compensation expense on a straight-line basis over the requisite service periods, which results in a weighted average period of approximately 1.72 years over which the unrecognized compensation expense is expected to be recognized. The total compensation cost related to all of the Company’s equity-based awards recognized during the years ended December 31, 2022, 2021 and 2020 was comprised as follows:
|  | Year ended December 31 |
|  | 2022 |  |  | 2021 |  |  | 2020 |
Research and development |  | $ | 144 |  |  | $ | 94 |  |  | $ | 60 |
Sales and marketing |  |  | 49 |  |  |  | 45 |  |  |  | 48 |
General and administrative |  |  | 29 |  |  |  | 18 |  |  |  | 12 |
|  | $ | 222 |  |  | $ | 157 |  |  | $ | 120 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI https://asc.fasb.org/topic&trid=2228938 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (l) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration